LIVIVO - Search results -

Search results

Result 1 - 10 of total 71

Search options

Article ; Online: Reply to S. Zhang.

Lattanzi, Michael / Funt, Samuel A / Rosenberg, Jonathan E

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022 Volume 40, Issue 23, Page(s) 2657–2658

Language	English
Publishing date	2022-05-24
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.22.00809
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.

Matulewicz, Richard S / Benfante, Nicole / Funt, Samuel A / Feldman, Darren R / Carver, Brett / Doudt, Alexander / Knezevic, Andrea / Sheinfeld, Joel

The Journal of urology

2023 Volume 211, Issue 1, Page(s) 80–89

Abstract: Purpose: Primary surgical treatment with retroperitoneal lymph node dissection aims to accurately stage and treat patients with node-positive pure seminoma while avoiding long-term risks of chemotherapy or radiation, traditional standard-of-care ... ...

Abstract	Purpose: Primary surgical treatment with retroperitoneal lymph node dissection aims to accurately stage and treat patients with node-positive pure seminoma while avoiding long-term risks of chemotherapy or radiation, traditional standard-of-care treatments. Materials and methods: We reported the pathologic and oncologic outcomes of patients with pure seminoma treated with primary retroperitoneal lymph node dissection in a retrospective, single-institution case series over 10 years. The primary outcome was 2-year recurrence-free survival stratified by adjuvant management strategy (surveillance vs adjuvant chemotherapy). Results: Forty-five patients treated with primary retroperitoneal lymph node dissection for pure testicular seminoma metastatic to the retroperitoneum were identified. Median size of largest lymph node before surgery was 1.8 cm. Viable germ cell tumor, all of which was pure seminoma, was found in 96% (n=43) of patients. The median number of positive nodes and nodes removed was 2 and 54, respectively. Median positive pathologic node size was 2 cm (IQR 1.4-2.5 cm, range 0.1-5 cm). Four of 29 patients managed with postoperative surveillance experienced relapse; 2-year recurrence-free survival was 81%. Median follow-up for those managed with surveillance who did not relapse was 18.5 months. There were no relapses in the retroperitoneum, visceral recurrences, or deaths. Among the 16 patients who received adjuvant treatment, 1 patient experienced relapse in the pelvis at 19 months. Conclusions: Primary retroperitoneal lymph node dissection for pure seminoma with low-volume metastases to the retroperitoneum is safe and effective, allowing most patients to avoid long-term toxicities from chemotherapy or radiation.
MeSH term(s)	Male ; Humans ; Retrospective Studies ; Seminoma/surgery ; Seminoma/pathology ; Neoplasm Recurrence, Local/pathology ; Testicular Neoplasms/surgery ; Testicular Neoplasms/pathology ; Lymph Node Excision/adverse effects ; Neoplasms, Germ Cell and Embryonal/pathology ; Retroperitoneal Space/pathology ; Adjuvants, Immunologic ; Recurrence ; Neoplasm Staging
Chemical Substances	Adjuvants, Immunologic
Language	English
Publishing date	2023-09-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	3176-8
ISSN	1527-3792 ; 0022-5347
ISSN (online)	1527-3792
ISSN	0022-5347
DOI	10.1097/JU.0000000000003697
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.91: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 331: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary Tract.

Donat, Sherri M / Sonoda, Yukio / Al-Ahmadie, Hikmat / Murali, Rajmohan / Ng, Dianna L / Funt, Samuel A / Park, Kay J

Urology

2023 Volume 173, Page(s) 10–16

Abstract: Urinary cytology is indispensable both for the evaluation of gross hematuria and surveillance of patients with urothelial neoplasms. A positive urine cytology usually indicates the presence of urothelial carcinoma somewhere in the urinary tract. However, ...

Abstract	Urinary cytology is indispensable both for the evaluation of gross hematuria and surveillance of patients with urothelial neoplasms. A positive urine cytology usually indicates the presence of urothelial carcinoma somewhere in the urinary tract. However, in women, it may also signal urothelial carcinoma involvement of the lower gynecologic tract or be the presenting sign for a primary cancer of the lower gynecologic tract or rectum. Guidelines for the evaluation of women with a positive cytology and normal urinary tract are lacking. We present a review of the current literature with case scenarios to bring clinicians attention to this diagnostic dilemma.
MeSH term(s)	Humans ; Female ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/pathology ; Urinary Bladder Neoplasms/pathology ; Cytology ; Urinary Tract/pathology ; Urologic Neoplasms/diagnosis ; Urine
Language	English
Publishing date	2023-01-06
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	192062-5
ISSN	1527-9995 ; 0090-4295
ISSN (online)	1527-9995
ISSN	0090-4295
DOI	10.1016/j.urology.2022.12.032
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 275: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Funt, Samuel A / Rosenberg, Jonathan E

Nature reviews. Clinical oncology

2017 Volume 14, Issue 4, Page(s) 221–234

Abstract: Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from ... ...

Abstract	Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from bladder cancer. Insufficient evidence is available to fully support the use of such chemotherapy in the adjuvant setting; however, neoadjuvant cisplatin-based combination chemotherapy has become a standard of care for eligible patients based on the improved disease-specific and overall survival demonstrated in two randomized phase III trials, compared with surgery alone. For patients with disease downstaging to non-MIBC at the time of radical cystectomy as a result of neoadjuvant chemotherapy, outcomes are outstanding, with 5-year overall survival of 80-90%. Nevertheless, the inability to define before treatment the patients who will and those who will not achieve such a response has impeded the achievement of better outcomes for patients with MIBC. High-throughput DNA and RNA profiling technologies might help to overcome this barrier and enable a more-personalized approach to the use of cytotoxic neoadjuvant chemotherapy. In the past 2 years, trial results have demonstrated the unprecedented ability of immune- checkpoint blockade to induce durable remissions in patients with metastatic disease that has progressed after chemotherapy; studies are now urgently needed to determine how best to incorporate this powerful therapeutic modality into the care of patients with MIBC. Herein, we review the evolution of chemotherapy and immunotherapy for muscle-invasive bladder cancer.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/metabolism ; Chemotherapy, Adjuvant ; Cisplatin/administration & dosage ; Cystectomy/methods ; Cystectomy/mortality ; DNA Repair/genetics ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Evidence-Based Medicine ; Humans ; Immunotherapy/methods ; Immunotherapy/mortality ; Lymphatic Metastasis ; Muscle Neoplasms/drug therapy ; Muscle Neoplasms/mortality ; Muscle Neoplasms/surgery ; Mutation/genetics ; Neoplasm Invasiveness ; Neoplasm Staging ; Organ Sparing Treatments/methods ; Organ Sparing Treatments/mortality ; Preoperative Care/methods ; Randomized Controlled Trials as Topic ; Time Factors ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/surgery
Chemical Substances	Biomarkers, Tumor ; Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2017
Publishing country	England
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	2491410-1
ISSN	1759-4782 ; 1759-4774
ISSN (online)	1759-4782
ISSN	1759-4774
DOI	10.1038/nrclinonc.2016.188
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6029: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 103: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Extramammary Paget Disease. Part II. Evidence-based Approach to Management.

Shah, Rohan R / Shah, Kalee / Wilson, Britney N / Leitao, Mario M / Smogorzewski, Jan / Crane, Christopher / Funt, Samuel A / Hosein, Sharif / Dafinone, Mirabel / Rossi, Anthony

Journal of the American Academy of Dermatology

2024

Abstract: Extramammary Paget disease is a rare cutaneous malignancy that most commonly affects the genitals, perianal area, and axilla of elderly patients. Delays in care often lead to high levels of disease burden for patients. Thus, evidence-based ... ...

Abstract	Extramammary Paget disease is a rare cutaneous malignancy that most commonly affects the genitals, perianal area, and axilla of elderly patients. Delays in care often lead to high levels of disease burden for patients. Thus, evidence-based recommendations are paramount in mitigating morbidity and mortality for this unique patient population. This 2-part continuing medical education series provides a complete picture of extramammary Paget disease. Part 2 of this continuing medical education series focuses on the complex management of extramammary Paget disease including surgical and non-invasive therapies, as well as novel approaches for advanced disease.
Language	English
Publishing date	2024-04-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2023.07.1052
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.

Vanguri, Rami S / Smithy, James W / Li, Yanyun / Zhuang, Mingqiang / Maher, Colleen A / Aleynick, Nathaniel / Peng, Xiyu / Al-Ahmadie, Hikmat / Funt, Samuel A / Rosenberg, Jonathan E / Iyer, Gopa / Bajorin, Dean / Mathews, James C / Nadeem, Saad / Panageas, Katherine S / Shen, Ronglai / Callahan, Margaret K / Hollmann, Travis J

The Journal of pathology

2023 Volume 261, Issue 3, Page(s) 349–360

Abstract: As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue-based immune biomarkers of clinical benefit to ICIs using multiplex ... ...

Abstract	As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue-based immune biomarkers of clinical benefit to ICIs using multiplex immunofluorescence and to integrate these findings with previously identified peripheral blood biomarkers of response. Fifty-five pretreatment and 12 paired on-treatment UC specimens were identified from patients treated with nivolumab with or without ipilimumab. Whole tissue sections were stained with a 12-plex mIF panel, including CD8, PD-1/CD279, PD-L1/CD274, CD68, CD3, CD4, FoxP3, TCF1/7, Ki67, LAG-3, MHC-II/HLA-DR, and pancytokeratin+SOX10 to identify over three million cells. Immune tissue densities were compared to progression-free survival (PFS) and best overall response (BOR) by RECIST version 1.1. Correlation coefficients were calculated between tissue-based and circulating immune populations. The frequency of intratumoral CD3
Language	English
Publishing date	2023-09-05
Publishing country	England
Document type	Journal Article
ZDB-ID	3119-7
ISSN	1096-9896 ; 0022-3417
ISSN (online)	1096-9896
ISSN	0022-3417
DOI	10.1002/path.6197
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.12: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 'Case of the Month' from Memorial Sloan Kettering Cancer Center, New York, NY, USA: managing newly diagnosed metastatic testicular germ cell tumour in a COVID-19-positive patient.

Almassi, Nima / Mulhall, John P / Funt, Samuel A / Sheinfeld, Joel

BJU international

2020 Volume 126, Issue 3, Page(s) 333–335

MeSH term(s)	Adolescent ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/therapy ; Humans ; Male ; Neoplasms, Germ Cell and Embryonal/diagnosis ; Neoplasms, Germ Cell and Embryonal/surgery ; Neoplasms, Germ Cell and Embryonal/virology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/therapy ; SARS-CoV-2 ; Testicular Neoplasms/diagnosis ; Testicular Neoplasms/surgery ; Testicular Neoplasms/virology
Keywords	covid19
Language	English
Publishing date	2020-08-18
Publishing country	England
Document type	Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1462191-5
ISSN	1464-410X ; 1464-4096 ; 1358-8672
ISSN (online)	1464-410X
ISSN	1464-4096 ; 1358-8672
DOI	10.1111/bju.15157
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.107: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 13: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Funt, Samuel A / Chapman, Paul B

Clinical cancer research : an official journal of the American Association for Cancer Research

2016 Volume 22, Issue 10, Page(s) 2323–2328

Abstract: The relatively low success rate of phase II oncology trials in predicting success of novel drugs in phase III trials and in gaining regulatory approval may be due to reliance on the endpoint of response rate defined by the RECIST. The neoadjuvant ... ...

Abstract	The relatively low success rate of phase II oncology trials in predicting success of novel drugs in phase III trials and in gaining regulatory approval may be due to reliance on the endpoint of response rate defined by the RECIST. The neoadjuvant treatment paradigm allows the antitumor activity of a novel therapy to be determined on a pathologic basis at the time of surgery instead of by RECIST, which was not developed to guide clinical decision making or correlate with long-term outcomes. Indeed, the FDA endorsed pathologic complete response (pCR) as a surrogate for overall survival (OS) in early-stage breast cancer and granted accelerated approval to pertuzumab based on this endpoint. We propose that pCR is a biologically rational method of determining treatment effect that may be more likely to predict OS. We discuss some advantages of the neoadjuvant trial design, review the use of neoadjuvant therapy as standards of care, and consider the neoadjuvant platform as a method for drug development. Clin Cancer Res; 22(10); 2323-8. ©2016 AACR.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Neoadjuvant Therapy/methods ; Neoplasms/drug therapy
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2016--15
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-15-1961
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A New Twist to an Old Tale: Immunotherapy in Non-muscle-invasive Bladder Cancer.

Funt, Samuel A / Pietzak, Eugene J / Bajorin, Dean F

European urology oncology

2018 Volume 1, Issue 3, Page(s) 199–201

MeSH term(s)	Humans ; Immunologic Factors ; Immunotherapy ; Urinary Bladder Neoplasms
Chemical Substances	Immunologic Factors
Language	English
Publishing date	2018-07-24
Publishing country	Netherlands
Document type	Editorial ; Comment
ISSN	2588-9311
ISSN (online)	2588-9311
DOI	10.1016/j.euo.2018.07.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.

Adra, Nabil / Vaughn, David J / Einhorn, Lawrence H / Hanna, Nasser H / Funt, Samuel A / Rosales, Matt / Arozullah, Ahsan / Feldman, Darren R

Investigational new drugs

2022 Volume 40, Issue 5, Page(s) 1087–1094

Abstract: Claudin6(CLDN6) is a tight junction protein of claudin-tetraspanin family and is of the earliest molecules expressed in embryonic epithelium. CLDN6 is frequently aberrantly expressed in testicular germ-cell tumors(GCT). ASP1650 is a chimeric-mouse/human- ... ...

Abstract	Claudin6(CLDN6) is a tight junction protein of claudin-tetraspanin family and is of the earliest molecules expressed in embryonic epithelium. CLDN6 is frequently aberrantly expressed in testicular germ-cell tumors(GCT). ASP1650 is a chimeric-mouse/human-IgG1 antibody directed against CLDN6. Two-part, open-label, phase-II trial investigating ASP1650 in patients with relapsed/refractory GCT and no curable options. Part1 was a safety lead-in to establish the recommended-phase-II-dose(RP2D). Part2 was a phase-II study designed to evaluate the antitumor effects of ASP1650. CLDN6 expression was centrally assessed on archival tumor tissue using immunohistochemistry. The primary objectives were to establish the RP2D(safety lead-in) and the antitumor activity(phase-II) of ASP1650. Nineteen male patients were enrolled: 6 patients in 1000 mg/m
MeSH term(s)	Adult ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/adverse effects ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Testicular Neoplasms/drug therapy ; Young Adult
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents
Language	English
Publishing date	2022-06-27
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604895-x
ISSN	1573-0646 ; 0167-6997
ISSN (online)	1573-0646
ISSN	0167-6997
DOI	10.1007/s10637-022-01276-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1823: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito